MFAM
RARE icon

Motley Fool Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Motley Fool Asset Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.64M Buy
78,141
+5,693
+8% +$128K 0.07% 152
2025
Q4 		$1.67M Sell
72,448
-10,152
-12% -$334K 0.06% 155
2025
Q3 		$2.48M Sell
82,600
-84,848
-51% -$2.54M 0.1% 139
2025
Q2 		$6.09M Buy
167,448
+82,975
+98% +$2.99M 0.28% 70
2025
Q1 		$3.06M Buy
84,473
+36,025
+74% +$1.5M 0.17% 107
2024
Q4 		$2.04M Sell
48,448
-93,201
-66% -$4.62M 0.11% 136
2024
Q3 		$8M Buy
141,649
+360
+0.3% +$18.3K 0.47% 57
2024
Q2 		$5.81M Sell
141,289
-5,237
-4% -$224K 0.39% 65
2024
Q1 		$6.84M Sell
146,526
-2,917
-2% -$138K 0.44% 63
2023
Q4 		$7.15M Sell
149,443
-6,661
-4% -$258K 0.53% 55
2023
Q3 		$5.57M Buy
156,104
+64,416
+70% +$2.55M 0.45% 59
2023
Q2 		$4.23M Buy
91,688
+57,097
+165% +$2.65M 0.38% 61
2023
Q1 		$1.39M Sell
34,591
-2,372
-6% -$102K 0.15% 87
2022
Q4 		$1.71M Sell
36,963
-3,151
-8% -$124K 0.19% 92
2022
Q3 		$1.66M Sell
40,114
-42,092
-51% -$2.16M 0.16% 98
2022
Q2 		$5.25M Sell
82,206
-5,631
-6% -$347K 0.49% 54
2022
Q1 		$6.38M Sell
87,837
-32,156
-27% -$2.24M 0.47% 54
2021
Q4 		$10.1M Sell
119,993
-14,364
-11% -$1.17M 0.65% 48
2021
Q3 		$12.1M Sell
134,357
-36,639
-21% -$3.31M 0.79% 41
2021
Q2 		$16.3M Buy
170,996
+18,670
+12% +$1.95M 1.08% 28
2021
Q1 		$17.3M Buy
152,326
+96,990
+175% +$13.2M 1.25% 24
2020
Q4 		$7.66M Buy
55,336
+9,990
+22% +$1.19M 0.57% 52
2020
Q3 		$3.89M Buy
45,346
+2,997
+7% +$248K 0.35% 66
2020
Q2 		$3.31M Buy
42,349
+13,584
+47% +$899K 0.33% 64
2020
Q1 		$1.28M Buy
+28,765
New +$1.49M 0.17% 89

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Motley Fool Asset Management's RARE Position: Q1 2026 in Review

Motley Fool Asset Management increased its Ultragenyx Pharmaceutical (RARE) stake by 7.9% in Q1 2026, buying an estimated $128K and bringing the position to 78,141 shares worth $1.64M. The position accounts for 0.07% of the portfolio, ranked #152.

Motley Fool Asset Management first reported a position in RARE in Q1 2020 and has held it in 25 quarters since. The position peaked at $17.3M in Q1 2021. 296 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Motley Fool Asset Management held 78,141 shares of Ultragenyx Pharmaceutical worth $1.64M as of Q1 2026.
  • Motley Fool Asset Management bought 5,693 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $128K.
  • Ultragenyx Pharmaceutical made up 0.07% of Motley Fool Asset Management's portfolio in Q1 2026, its #152 holding.
  • Motley Fool Asset Management first reported a position in Ultragenyx Pharmaceutical in Q1 2020 and has held it in 25 quarters since.
  • Motley Fool Asset Management's Ultragenyx Pharmaceutical position peaked at $17.3M in Q1 2021.
  • 296 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Motley Fool Asset Management's 13F filing for Q1 2026, filed 12 May 2026.